Your browser is old and is not supported. Upgrade for better security.

Invest in Quorum X Diagnostics

The first 4-minute at-home Antigen test for COVID

Pitch Video
Investor Panel


The first 4-minute, fully at-home COVID Antigen test.
No prescription needed; an OTC test kit identifying an active COVID infection in less than 4 mins.
Resubmitting our application to FDA for Emergency use authorization soon.
Our Team! Our team consists of 5 doctors and an army of Interns.
Completed-YCombinator Online StartUp School.
Presently in the "testing the waters,"phase* Presently, we are only taking reservations.

Our Team

Global need. We realized we could use the same unique technology (that was used to build our QXD-1 Fast test for Pseudomonal Pneumonia) and use it to build a test for COVID.

The first 4-minute at-home Antigen test for COVID

We are 'testing the waters' to gauge investor interest in an offering under Regulation Crowdfunding. No money or other consideration is being solicited. If sent, it will not be accepted. No offer to buy securities will be accepted. No part of the purchase price will be received until a Form C is filed and only through Wefunder’s platform. Any indication of interest involves no obligation or commitment of any kind. Presently, we are only taking Reservations!

Quorum X Diagnostics (QXD), is a medical diagnostics startup that was founded in 2017 to produce an effective yet simple and fast diagnostic test for Pseudomonas pneumonia to be used in physicians’ offices and/or clinics. The idea is that the test would provide real-time results without having to send samples off to a lab. 

In the Spring of 2020, in the wake of the COVID-19 pandemic, the scientific team quickly realized that the same unique proprietary technology could be used to develop an at-home diagnostic test for SARS-CoV-2 (COVID-19) that would provide real-time results in 4 minutes and detect an active COVID-19 infection (even if an individual is asymptomatic). 

An Emergency Use Authorization (EUA) has been submitted to the U. S. FDA.        EUA approval is pending. (Please note:  the image above is a design prototype)

During this transition period from quarantine and isolation to regaining life as it was before the pandemic, the need for rapid testing for Covid continues. 


  • The 4-minute COVIDNOW® antigen test currently has the fastest development time compared to competitive products that currently have EUA approval.
  • COVIDNOW® is SIMPLE. It was designed to be easy to make self-testing at-home a viable option for everyone!
  • QXD’s COVIDNOW® test is an antigen test vs. an antibody test meaning it can detect active infection.
  • The sensitivity of the COVIDNOW® test is able to detect an active infection in asymptomatic individuals.
  • COVIDNOW® does not require a prescription.
  • The COVIDNOW® APP uses the latest in A.I. technology making it possible to analyze the test cassette result much sharper than that of the naked eye. 
  • The sample from the COVIDNOW® test does not have to be sent off to a lab; it is not a collection kit.
  • Everything needed to complete the test is included in the COVIDNOW® test kit package.
  • QXD has partnered with Physician 360, a telemedicine service, to provide immediate connectivity to a board-certified physician for a consultation.
  • The QXD COVIDNOW® at-home test kit has a mobile phone APP that using AI technology and works in conjunction with the telemedicine service.
  • QXD's partnership with Physician 360, the telemedicine service, provides an additional distribution channel through P360 kiosks located in 1,000+ stores across all 50 states.
  • All patent applications required for the proprietary technology used to produce QXD’s rapid diagnostic tests have been submitted and are currently pending.
  • Clinical trials have been finalized and the application for an Emergency Use Authorization (EUA) has been submitted to the FDA.
  • Should Quorum X Diagnostics not receive the EUA from the FDA, it still has the QXD-1 Fast Test for Pseudomonal pneumonia as well as other similar rapid diagnostics tests in the pipeline.
  • QXD has a clear exit strategy. Within five years continue the development of the proprietary technology and build out the scientific and organizational infrastructure of the business model at which point it would be optimal for a larger corporation to take the vision to the next level.
  •  COVIDNOW® is pending EUA approval

Making an investment is a huge decision and one that we don’t take lightly. Rest assured, we are dedicated, determined, and passionate about what we are doing.

QXD has an amazing team and we're the team to get it DONE!